Veterinary Dermatology Drugs Market, By Type of Drug (Antibiotics, Antifungal drugs, Anti-inflammatory drugs, Immunotherapy drugs, Parasiticides, Others), By Animal Type (Dogs, Cats, Horses, Others), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
The global veterinary dermatology drugs market size was valued at US$ 2.43 billion in 2022 and is expected to reach US$ 4.39 billion by end of 2030, growing at a CAGR of 7.67%. The growth of this market is attributed to the rising incidence of skin diseases in animals, the growing adoption of pets, and increasing awareness about animal healthcare.
Factors such as the growing prevalence of allergies in animals, advancements in veterinary medicine, and the increasing demand for novel drugs for animal skin diseases are expected to boost the market growth in the coming years. The report also highlights that the increasing adoption of companion animals and the growing demand for personalized animal care are expected to provide lucrative opportunities for market players in the veterinary dermatology drugs market.
North America dominated the global veterinary dermatology drugs market in 2020, accounting for the largest revenue share of over 40%. This is attributed to the high adoption of companion animals, the presence of leading market players, and the availability of advanced veterinary healthcare infrastructure in the region.
The Asia Pacific region is expected to witness the fastest growth in the veterinary dermatology drugs market during the forecast period from 2022 to 2030. The growth is attributed to the increasing adoption of companion animals in emerging countries such as China and India, rising awareness about animal health, and increasing investments in the veterinary healthcare sector.
Europe is also expected to witness significant growth in the veterinary dermatology drugs market, owing to the increasing prevalence of skin diseases in animals, the growing adoption of pets, and the presence of major market players in the region.
Veterinary Dermatology Drugs Market Drivers:
Increasing incidence of skin diseases in animals: The rising prevalence of skin diseases in animals, including allergies, infections, and parasites, is driving the demand for veterinary dermatology drugs.
Growing adoption of pets: The increasing adoption of companion animals, such as dogs and cats, is driving the demand for veterinary dermatology drugs, as these animals are prone to various skin diseases.
Advancements in veterinary medicine: The development of advanced veterinary medicines and technologies for the treatment of animal skin diseases is driving the growth of the veterinary dermatology drugs market.
Demand for novel drugs for animal skin diseases: The increasing demand for novel drugs and treatments for animal skin diseases is driving the growth of the veterinary dermatology drugs market. This is leading to the development of new and innovative drugs for the treatment of various skin diseases in animals.
Rising demand for organic and natural veterinary dermatology drugs: The growing demand for organic and natural products for the treatment of animal skin diseases presents a significant opportunity for market players to develop and offer new and innovative products to meet the needs of pet owners who prefer natural and organic products.
Increasing demand for personalized animal care: The rising demand for personalized care and treatment for pets presents an opportunity for market players to offer customized solutions for the treatment of animal skin diseases, including personalized medication and treatment plans.
Advancements in drug delivery technologies: The development of advanced drug delivery technologies, such as transdermal patches and injectable sustained-release formulations, presents an opportunity for market players to develop and offer new and innovative products for the treatment of animal skin diseases.
Collaborations and partnerships: Collaborations and partnerships between market players, research institutes, and academic institutions present an opportunity for the development of new and innovative products for the treatment of animal skin diseases.
Veterinary Dermatology Drugs Market Trends:
Increasing use of biologics: The use of biologics, such as monoclonal antibodies, cytokines, and growth factors, for the treatment of animal skin diseases is gaining popularity, and this trend is expected to continue in the coming years.
Rising demand for prescription products: The rising demand for prescription products, such as antibiotics and antifungal agents, for the treatment of animal skin diseases is driving the growth of the veterinary dermatology drugs market.
Increasing popularity of telemedicine: The increasing popularity of telemedicine for the diagnosis and treatment of animal skin diseases is a growing trend in the veterinary dermatology drugs market.
Increasing use of topical products: The increasing use of topical products, such as ointments, creams, and gels, for the treatment of animal skin diseases is a trend that is expected to continue in the coming years due to their ease of application and localized treatment.
High cost of treatment: The high cost of veterinary dermatology drugs and treatments may limit the market growth, as pet owners may choose not to pursue treatment due to the high costs involved.
Side effects associated with drugs: The side effects associated with some of the veterinary dermatology drugs may limit the growth of the market, as pet owners may be reluctant to use these drugs due to concerns about potential adverse effects.
Stringent regulatory requirements: The stringent regulatory requirements for the approval of veterinary dermatology drugs may limit the growth of the market, as it may increase the time and cost required to bring new products to market.
Cytopoint: Zoetis launched Cytopoint, a monoclonal antibody therapy for the treatment of atopic dermatitis in dogs, in 2016. It offers a longer duration of effect than traditional therapies and reduces the need for frequent administration.
Galliprant: Elanco launched Galliprant, a novel non-steroidal anti-inflammatory drug for the treatment of pain and inflammation associated with osteoarthritis in dogs, in 2016. It has a targeted mechanism of action and is well-tolerated by dogs.
Osurnia: Elanco also launched Osurnia, a topical treatment for otitis externa (ear infections) in dogs, in 2016. It offers a single-dose administration and a favorable safety profile.
Atopica: Elanco's Atopica is an oral medication for the treatment of atopic dermatitis in dogs. It is an immunosuppressant that targets the immune system response that causes the disease.
Sileo: Zoetis launched Sileo, an oral medication for the treatment of noise aversion in dogs, in 2016. It reduces anxiety and fear associated with loud noises such as thunderstorms and fireworks.
Acquisition and partnerships
Elanco's acquisition of Bayer Animal Health: In 2020, Elanco completed its acquisition of Bayer Animal Health, expanding its portfolio of animal health products, including dermatology drugs for pets.
Zoetis' partnership with Kindred Biosciences: In 2020, Zoetis entered into a partnership with Kindred Biosciences to develop and market a monoclonal antibody therapy for the treatment of atopic dermatitis in dogs.
Zoetis' partnership with Ethos Veterinary Health: In 2020, Zoetis announced a partnership with Ethos Veterinary Health to improve access to dermatology care for pets across the United States, by providing advanced dermatology services and innovative treatments.
Dechra's partnership with MediBeacon: In 2020, Dechra announced a partnership with MediBeacon to develop a non-invasive diagnostic tool for the assessment of skin health in pets, enabling earlier detection and treatment of skin diseases.
Vetoquinol's acquisition of Clarion Biociências: In 2021, Vetoquinol announced its acquisition of Clarion Biociências, a Brazilian veterinary pharmaceutical company, to expand its presence in the Latin American market, including dermatology products.
Top companies in Veterinary Dermatology Drugs Market
Zoetis Inc.
Elanco Animal Health Incorporated
Boehringer Ingelheim International GmbH
Virbac
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
Bayer AG
Ceva Sante Animale
Kindred Biosciences, Inc.
IDEXX Laboratories, Inc.
These companies are leading players in the veterinary dermatology drugs market and offer a wide range of products for the treatment of various skin conditions in animals. They have a strong global presence and are investing heavily in research and development to further advance their technologies and stay ahead of the competition. Additionally, they are also expanding their distribution channels to reach a wider audience of veterinarians and pet owners.
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
The global Veterinary Dermatology Drugs Market size was valued at USD 2.43 billion in 2023 and is expected to reach USD 4.39 billion in 2030.
The global veterinary dermatology drugs market was valued at US$ 2.43 billion in 2022 and is expected to exhibit a CAGR of 7.67% between 2023 and 2030.
In 2020, North America dominated the market for veterinary dermatological medications worldwide.
Rising demand for organic and natural veterinary dermatology drugs is expected to drive the market
Rising prevalence of diseases among animals is the primary driving factor of the market.
Major players operating in the market include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Virbac, Vetoquinol S.A., Dechra Pharmaceuticals PLC, Bayer AG, Ceva Sante Animale, Kindred Biosciences, Inc., IDEXX Laboratories, Inc.
U.S.: 
U.K. : 
India : 
